Kestra Medical Technologies, Ltd. (KMTS)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Kestra Medical Technologies, Ltd. .
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 5 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 24.00 $ — 70% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/04/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AAQS
4/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% –
- Exp. sales growth 3Y > 5% 42.7%
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% 42.7%
- Net debt < 4x EBIT –
- EBIT positive, 10Y straight –
- Max. EBIT decline < 50% –
- Return on equity > 15% -50.7%
- ROCE > 15% -43.7%
- Expected return > 10% 30.3%
View all AAQS quality stocks · Read the methodology at AlleAktien
Source: fundamental data
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
5 of 10 Solid growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 131.8% passed
- More than 10% revenue growth is expected for the coming year 42.9% passed
- Share count grows by less than 3% a year 5.6% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") -63.5% failed
- Gross margin at 40% or higher and without meaningful erosion 51.4% passed
- Goodwill from acquisitions does not grow faster than revenue 0.0% passed
- Net debt below twice EBITDA 150 m net cash passed
- Operating cash flow covers the profits of the last three years 108 m failed
- Return on capital at 15% or higher, or up versus two years ago -43.7% failed
- Insiders hold at least 10% or are net buyers 5.3% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Analysts & Price Target
The price target sits 25.0% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 6
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 04/30/2027 | -2.31 | -2.33 – -2.28 | 137 | -34.9% | 2 |
| 04/30/2028 | -2.02 | -2.06 – -1.98 | 194 | 12.4% | 2 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -0.61 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.41 | – | 15 | – | -138.50 | -18 | -23 |
| 2025: Q1 | -0.43 | – | 15 | 82.30 | -142.50 | -18 | -22 |
| 2025: Q2 | -1.05 | – | 17 | 71.40 | -302.10 | -24 | -32 |
| 2025: Q3 | -0.50 | – | 19 | 51.50 | -133.30 | -26 | -34 |
| 2025: Q4 | -0.64 | – | 23 | 53.40 | -145.30 | -18 | -26 |
| 2026: Q1 | -0.61 | – | 25 | 62.70 | -139.20 | -18 | -28 |
| 2026: Q2 | -0.67 | 36.20 | 29 | 66.30 | -135.70 | -19 | -28 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2020 | 0 | -29 | -29 | -0.59 | -30 | 4 | 8 |
| 2021 | 0 | -33 | -34 | -0.69 | -30 | 2 | 31 |
| 2023 | 8 | -80 | -84 | -1.70 | -70 | -118 | 39 |
| 2024 | 28 | -85 | -94 | -1.90 | -72 | -209 | 46 |
| 2025 | 60 | -106 | -114 | -2.30 | -78 | 205 | 296 |
| 2026 | 95 | -135 | -132 | -2.25 | -82 | 260 | 358 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Kestra Medical Technologies, Ltd. ist ein Unternehmen für tragbare Medizingeräte und digitale Gesundheitsversorgung.
| Employees | 443 |
|---|---|
| Headquarters | Kirkland, WA |
| Address | 3933 Lake Washington Blvd NE, 98033 Kirkland, United States |
| Phone | 425 279 8002 |
| Website | kestramedical.com |
| IPO Date | 6. Mar 2025 |
| ISIN | BMG524411052 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Brian Webster | Founder, President, CEO & Director | 1964 |
| Traci S. Umberger | Co-Founder, General Counsel, Chief Administrative Officer, Secretary & Director | 1963 |
| Vaseem Mahboob | Chief Financial Officer | 1969 |
| Gordon Teddy | Chief Information Officer | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 16. Jul 2026 | Moran Timothy P. | Chief Business Officer | Other | 39,113 | 0.00 | – |
| 15. Jul 2026 | Ford Alfred J Jr | Chief Commercial Officer | Other | 58,832 | 0.00 | – |
| 15. Jul 2026 | Mahboob Vaseem | Chief Financial Officer | Other | 44,118 | 0.00 | – |
| 15. Jul 2026 | Umberger Traci S | See Remarks | Other | 58,832 | 0.00 | – |
| 15. Jul 2026 | Webster Brian Daniel | See Remarks | Sell | 3,000 | 24.00 | 71,995 |
| 15. Jul 2026 | Webster Brian Daniel | See Remarks | Sell | 784 | 22.63 | 17,745 |
| 15. Jul 2026 | Webster Brian Daniel | See Remarks | Sell | 11,216 | 22.01 | 246,870 |
| 15. Jul 2026 | Webster Brian Daniel | See Remarks | Other | 176,470 | 0.00 | – |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.